Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2015 Jul 24;10(7):e0133343. doi: 10.1371/journal.pone.0133343

Correction: In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis

Fernanda de Oliveira Demitto, Renata Claro Ribeiro do Amaral, Flaviane Granero Maltempe, Vera Lúcia Dias Siqueira, Regiane Bertin de Lima Scodro, Mariana Aparecida Lopes, Katiany R Caleffi-Ferracioli, Pedro Henrique Canezin, Rosilene Fressatti Cardoso
PMCID: PMC4514749  PMID: 26207741

The graph legends for Figs 1 and 2 are incorrect. The symbols for RIF and VP are switched. Please see the complete, correct Figs 1 and 2 here.

Fig 1. Time-kill curve of the Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A exposed to rifampicin (RIF), verapamil (VP), and RIF+VP combination for 7 days at 35–37°C.

Fig 1

Open in a new tab

Fig 2. Fluorometry assay.

Fig 2

Open in a new tab

Accumulation of EtBr in the Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A. The mycobacteria were loaded with 0.25 μg/ml EtBr in the presence of 0.5 × MIC of verapamil (VP), rifampicin (RIF), and RIF+VP combination for 7 days at 35–37°C.

Reference

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES